Kathryn Beal on Aftercare for Patients with Primary Brain Tumors

Video

Kathryn Beal discusses what aftercare looks like for patients with primary brain tumors who have recieved a combination of radiation treatment and chemotherapy.

Kathryn Beal, MD, of Memorial Sloan Kettering Cancer Center, discusses aftercare for patients who have undergone combination therapy for primary brain tumors.

Side effects from radiation therapy can include fatigue, neurological symptoms, and edema. When radiation is combined with immunotherapy treatments, the standard radiation side effects can be exacerbated. There are also side effects that are unique to immunotherapy

Recent Videos
Anne M. Reb, PhD, NP, discussing a nurse-led intervention for fear of cancer recurrence.
Ann H. Partridge, MD, MPH, in an interview with Oncology Nursing News at 2024 ESMO Congress.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
FDA on blue background

Virus Therapy Gets Orphan Drug Designation for Glioma Treatment

Ryan Scott
November 10th 2024
Article

The FDA granted an orphan drug designation to herpes simplex virus type 1 (HSV-1) oncolytic virus MB-108 for malignant glioma treatment.

The Vitals

Jacki Garcia and Kristin Hendrickson on Navigating Patients Through Phase 0 Trials

Lindsay Fischer
July 15th 2023
Podcast

Jacki Garcia, RN, BSN, CNRN; and Kristin Hendrickson, BA, RN, discuss phase 0 trials and how they can help expedite the research process for brain cancer therapies.

drawing of a brain on yellow background

MTX110 May Improve Survival in Glioblastoma

Russ Conroy
October 21st 2024
Article

An investigational formula of panobinostat called MTX110 may improve outcomes in patients with recurrent glioblastoma.

brain with a tumor in it

MR-Linac Reduced Radiation to Healthy Brain Tissue in Glioma

Russ Conroy
October 12th 2024
Article

Weekly MR-Linac adaptive radiotherapy limited exposure to normal brain tissue in patients with high-grade glioma.

Oncology Drugs Approved by the FDA in August 2024

Oncology Drugs Approved by the FDA in August 2024

Darlene Dobkowski, MA
September 3rd 2024
Article

Throughout August, the FDA approved drugs for the treatment of diseases including non-small cell lung cancer, cutaneous T-cell lymphoma, astrocytoma/oligodendroglioma, and endometrial cancer.

FDA Approves Vorasidenib to Treat Grade 2 Astrocytoma, Oligodendroglioma With IDH1, IDH2 Mutations

FDA Approves Vorasidenib to Treat Grade 2 Astrocytoma, Oligodendroglioma With IDH1, IDH2 Mutations

Darlene Dobkowski, MA
August 6th 2024
Article

This marks the first approval of a systemic therapy for patients with grade 2 astrocytoma or oligodendroglioma with an IDH1 or IDH2 mutation.

© 2024 MJH Life Sciences

All rights reserved.